Elisabeth Deibel, Patricia E Carreira, Madelon Vonk, Nicoletta Del Papa, Radim Bečvář, Alfredo Guillén-Del-Castillo, Corrado Campochiaro, Hadi Poormoghim, Sophie Liem, Maria-Grazia Lazzaroni, Alessandro Giollo, Arsène Mekinian, Jeska de Vries-Bouwstra, Maria De Santis, Alexandra Balbir-Gurman, Carina Mihai, Giacomo De Luca, Sergey Moiseev, Elisabetta Zanatta, Rosario Foti, Simona Rednic, Christopher Denton, Maurizio Cutolo, Laura Belloli, Paolo Airo, Liudmila Garzanova, Gianluca Moroncini, Murat İnanç, Stylianos Panopoulos, Jose-Luis Tandaipan, Emmanuel Chatelus, Edoardo Rosato, Masataka Kuwana, Sule Yavuz, Juan J Alegre-Sancho, Vanessa Smith, Gabriella Szűcs, Joerg Henes, Ignasi Rodríguez-Pintó, Fabiola Atzeni, Julia Spierings, Marie-Elise Truchetet, Marcin Milchert, Daniel Brito de Araujo, Gabriela Riemekasten, Vera Bernardino, Thierry Martin, Francesco Del Galdo, Alessandra Vacca, Fabian Mendoza, Øyvind Midtvedt, Giuseppe Murdaca, Tânia Santiago, Veronica Codullo, Fabio Cacciapaglia, Ulrich Walker, Cathrine Brunborg, Francesca Tirelli, Yannick Allanore, Daniel E Furst, Marco Matucci, Armando Gabrielli, Oliver Distler, Anna-Maria Hoffmann-Vold
OBJECTIVE: Outcome of COVID-19 patients improved over the pandemic, including patients with systemic rheumatic diseases. However, data on systemic sclerosis (SSc) patients are lacking. This study aimed to assess the outcome of SSc patients with COVID-19 over several waves. METHODS: SSc patients with COVID-19 registered in the European Scleroderma Trials and Research group (EUSTAR) were collected between April 2020 and April 2021. Patients were assigned to wave 1 to 3 depending on date of COVID-19...
September 4, 2023: Arthritis Care & Research